Why we need pneumococcal vaccine effectiveness studies

Affiliations

Comment

Katherine L O'Brien. Lancet Respir Med. 2016 May.

. 2016 May;4(5):343-5.

doi: 10.1016/S2213-2600(16)30046-7.

¹ International Vaccine Access Center, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21231, USA. Electronic address: klobrien@jhu.edu.

No abstract available

Comment on

Effectiveness of 13-valent pneumococcal conjugate vaccine for prevention of invasive pneumococcal disease in children in the USA: a matched case-control study.
Moore MR, Link-Gelles R, Schaffner W, Lynfield R, Holtzman C, Harrison LH, Zansky SM, Rosen JB, Reingold A, Scherzinger K, Thomas A, Guevara RE, Motala T, Eason J, Barnes M, Petit S, Farley MM, McGee L, Jorgensen JH, Whitney CG. Moore MR, et al. Lancet Respir Med. 2016 May;4(5):399-406. doi: 10.1016/S2213-2600(16)00052-7. Epub 2016 Mar 14. Lancet Respir Med. 2016. PMID: 26987984